TICKERNERD
Menu
CAPRCAPRHealthcare · Biotechnology

CAPR Stock Forecast: Capricor Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$6.29
−7.97% on the day

The 10 Wall Street analysts covering Capricor Therapeutics, Inc. hold a median 12-month price target of $6 — -4.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$365.7M
Ticker Nerd rank
13 / 100
Median analyst target
$6.00
Analysts covering
10
Total return, dividends reinvested
1W
−5.4%
1M
−68.2%
YTD
−78.2%
1Y
−10.4%
From 52W high
−82.2%
From 52W low
+63.4%
$4
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Capricor Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
60
Size
59
Quality
46
Accruals
27
Revisions
26
Value
26
Growth
25
Volatility
19
Issuance
7

Momentum (60): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26CAPRHigh $28.00Median $6.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
1 Buy9 Hold0 Sell
Low $2.00Median $6.00High $28.00

The green dot is the last close — the median target sits −4.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Cantor FitzgeraldUpgradeOverweight$3.50 → $28
31 July 2026Jones TradingDowngradeHold—
31 July 2026Jones TradingDowngradeHold—
30 July 2026Cantor FitzgeraldDowngradeNeutral$62 → $3.50
30 July 2026Cantor FitzgeraldDowngradeNeutral—
30 July 2026HC Wainwright & Co.DowngradeNeutral—
30 July 2026HC Wainwright & Co.DowngradeNeutral—
30 July 2026Piper SandlerDowngradeNeutral—
30 July 2026Piper SandlerDowngradeNeutral$58 → $2.00
13 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026HC Wainwright & Co.ReiteratesBuy$60
13 Mar 2026B. Riley SecuritiesMaintainsBuy—
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
13 Mar 2026Piper SandlerReiteratesOverweight—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025B. Riley SecuritiesReiteratesBuy—
10 Dec 2025Piper SandlerReiteratesOverweight—
8 Dec 2025OppenheimerMaintainsOutperform—
4 Dec 2025Maxim GroupMaintainsBuy—
3 Dec 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CAPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Capricor Therapeutics, Inc. (CAPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−73.7%

Higher than 16% of US stocks

Return on assets
−33.6%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CAPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAPRCapricor Therapeutics, Inc.$365.7M
13
AGENAgenus, Inc.$362.0M
88
ZNTLZentalis Pharmaceuticals, Inc.$362.1M
63
PALIPalisade Bio, Inc.$366.0M
36
GALTGalectin Therapeutics, Inc.$371.1M
76
IPSCCentury Therapeutics, Inc.$371.9M
40
DMACDiaMedica Therapeutics, Inc.$351.6M
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Capricor Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAPR news & analysis

Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 21 Aug 2026negative

Glancy Prongay Wolke & Rotter LLP announced that investors who suffered losses on Capricor Therapeutics investments have an opportunity to lead a securities fraud class action lawsuit against the company, with a lead plaintiff deadline of September 28, 2026.

Why it matters — CAPR watchers would care because the announcement signals an active securities fraud lawsuit against the company that investors may be eligible to join.

FAQ

Frequently asked questions about CAPR stock

What is the CAPR stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Capricor Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $2 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAPR stock a buy right now?

Of the 10 analysts covering Capricor Therapeutics, Inc., 1 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Capricor Therapeutics, Inc. 13 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAPR?

As at 22 Aug 2026, Capricor Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (60 of 100).

Will CAPR stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies -4.6% from the last close, and Ticker Nerd's factor model ranks Capricor Therapeutics, Inc. 13 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAPR stock forecast for 2030?

No analyst covering Capricor Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $28 over the next 12 months.

How has CAPR stock performed over the past year?

Capricor Therapeutics, Inc. returned -10.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases with high unmet medical need.

What is the latest news on CAPR?

The most recent item we track (PRNewsWire, 21 Aug 2026): "Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit". Glancy Prongay Wolke & Rotter LLP announced that investors who suffered losses on Capricor Therapeutics investments have an opportunity to lead a securities fraud class action lawsuit against the company, with a lead plaintiff deadline of September 28, 2026.

Company

About Capricor Therapeutics, Inc.

Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases with high unmet medical need. The company concentrates particularly on Duchenne muscular dystrophy, targeting both skeletal and cardiac muscle complications associated with this progressive disorder. Capricor’s lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy being evaluated in late-stage clinical trials for Duchenne muscular dystrophy, supported by multiple Phase 3 and long-term extension studies. Beyond Deramiocel, Capricor is advancing a pipeline of exosome-based candidates aimed at leveraging engineered extracellular vesicles as delivery platforms in severe and difficult-to-treat conditions. Headquartered in San Diego, California, Capricor operates within the biotechnology and medical research segment of the healthcare sector, engaging with regulators, clinicians, and patient communities to bring advanced biological therapies toward potential commercialization. Through its specialized focus on rare neuromuscular and related diseases, the company plays a distinct role in the emerging field of regenerative and cell-based medicine.

CEO Dr. Linda Marbán Ph.D. · 231 employees · United States · https://www.capricor.com